Icon and Parexel partner with B-MS to support clinical dev

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial

Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.

The deals give B-MS the extra capacity it believes is needed to cope with an expected spike in clinical development. This spike is a consequence of compounds from its “robust internal pipeline​” and “significant inlicensing activity​” passing through clinical trials, said B-MS.

Icon and Parexel will provide the big pharma with “support for full development activities​”, a B-MS spokesperson told Outsourcing-Pharma. B-MS said Icon and Parexel will support its in-house capabilities and capacity with services that “can drive efficiency and cost savings​”.

Services covered by the deals include site management, data handling and monitoring of clinical studies for Phase IIb to IV trials. The spokesperson was unable to say how work will be divided between Icon and Parexel.

B-MS has inked three-year deals with both contract research organisations (CRO). The spokesperson said B-MS is outsourcing to two CROs, as opposed to one, because it believes it is “the best way to channel volume of work while ensuring some level of risk mitigation​”.

Icon and Parexel were chosen “based on their expertise, global reach, governance structure, willingness to partner, as well as their commitment to continuous improvement​”, said the spokesperson.

Over the last ten years, we have forged a strong partnership by working hard to fully understand B-MS’ unique requirements​”, said John Hubbard, Icon group president clinical research services.

Josef von Rickenbach, chairman and CEO of Parexel, said the partnership “is representative of leading models for outsourcing​” and that it can “increase efficiency and create significant value​”.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more